Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Glaxo gets Advair reprieve, but HIV competition bites
Generic versions of Glaxosmithkline's Advair have been delayed again, but doubts about the group's HIV doublets are creeping in.
